AbCellera Biologics (ABCL) Depreciation & Amortization (CF) (2020 - 2026)
AbCellera Biologics (ABCL) posted Depreciation & Amortization (CF) of $5.9 million for Q1 2026, up 15.16% on a QoQ basis from $5.1 million in Q4 2025, and up 34.5% year-over-year from $4.4 million in Q1 2025.
AbCellera Biologics (ABCL) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
AbCellera Biologics' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $5.9 million for Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 34.5% year-over-year to $5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.9 million (up 44.94% YoY) and the FY2025 annual result came in at $18.4 million, up 47.51% from the prior year.
- Depreciation & Amortization (CF) was $5.9 million for Q1 2026 at AbCellera Biologics, up from $5.1 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $5.9 million in Q1 2026 and bottomed at $1.4 million in Q1 2022.
- A 5-year average of $3.4 million and a median of $3.2 million in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) tumbled 45.93% — and 2025, when it surged 144.71%.
- AbCellera Biologics' Depreciation & Amortization (CF) stood at $2.7 million in 2022, then soared by 41.7% to $3.9 million in 2023, then tumbled by 45.93% to $2.1 million in 2024, then jumped by 144.71% to $5.1 million in 2025, then advanced by 15.16% to $5.9 million in 2026.
- Business Quant data shows ABCL's Depreciation & Amortization (CF) at $5.9 million in Q1 2026, $5.1 million in Q4 2025, and $4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | AbCellera Biologics | 1.72 Bn | 1.72 Bn | - | 5.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.92 Mn |
| Mar 31, 2026 | 5.92 Mn |
| Dec 31, 2025 | 5.14 Mn |
| Dec 31, 2025 | 5.14 Mn |
| Sep 30, 2025 | 4.30 Mn |
| Sep 30, 2025 | 4.30 Mn |
| Jun 30, 2025 | 4.50 Mn |
| Jun 30, 2025 | 4.50 Mn |
| Mar 31, 2025 | 4.40 Mn |
| Mar 31, 2025 | 4.40 Mn |
| Dec 31, 2024 | 2.10 Mn |
| Dec 31, 2024 | 2.10 Mn |
| Sep 30, 2024 | 3.80 Mn |
| Sep 30, 2024 | 3.80 Mn |
| Jun 30, 2024 | 3.40 Mn |
| Jun 30, 2024 | 3.40 Mn |
| Mar 31, 2024 | 3.20 Mn |
| Mar 31, 2024 | 3.20 Mn |
| Dec 31, 2023 | 3.88 Mn |
| Dec 31, 2023 | 3.88 Mn |